Barclays’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $0 | Sell |
2
-4,436
| -100% | – | ﹤0.01% | 4604 |
|
2025
Q1 | $19K | Buy |
4,438
+1,437
| +48% | +$6.15K | ﹤0.01% | 4071 |
|
2024
Q4 | $21K | Sell |
3,001
-133
| -4% | -$931 | ﹤0.01% | 4108 |
|
2024
Q3 | $45K | Buy |
3,134
+2,513
| +405% | +$36.1K | ﹤0.01% | 3938 |
|
2024
Q2 | $45K | Sell |
621
-838
| -57% | -$60.7K | ﹤0.01% | 3709 |
|
2024
Q1 | $86K | Sell |
1,459
-1,405
| -49% | -$82.8K | ﹤0.01% | 3693 |
|
2023
Q4 | $210K | Buy |
2,864
+2,501
| +689% | +$183K | ﹤0.01% | 3486 |
|
2023
Q3 | $14K | Sell |
363
-54
| -13% | -$2.08K | ﹤0.01% | 3977 |
|
2023
Q2 | $24K | Sell |
417
-1,275
| -75% | -$73.4K | ﹤0.01% | 3936 |
|
2023
Q1 | $110K | Buy |
+1,692
| New | +$110K | ﹤0.01% | 3473 |
|
2022
Q2 | – | Sell |
-213
| Closed | -$17K | – | 4935 |
|
2022
Q1 | $17K | Sell |
213
-1,377
| -87% | -$110K | ﹤0.01% | 4372 |
|
2021
Q4 | $146K | Buy |
1,590
+1,055
| +197% | +$96.9K | ﹤0.01% | 2898 |
|
2021
Q3 | $67K | Buy |
535
+364
| +213% | +$45.6K | ﹤0.01% | 3333 |
|
2021
Q2 | $20K | Sell |
171
-869
| -84% | -$102K | ﹤0.01% | 3726 |
|
2021
Q1 | $157K | Buy |
1,040
+638
| +159% | +$96.3K | ﹤0.01% | 3218 |
|
2020
Q4 | $46K | Sell |
402
-175
| -30% | -$20K | ﹤0.01% | 3208 |
|
2020
Q3 | $44K | Sell |
577
-113
| -16% | -$8.62K | ﹤0.01% | 3335 |
|
2020
Q2 | $76K | Buy |
690
+263
| +62% | +$29K | ﹤0.01% | 3232 |
|
2020
Q1 | $46K | Sell |
427
-863
| -67% | -$93K | ﹤0.01% | 3132 |
|
2019
Q4 | $205K | Buy |
1,290
+654
| +103% | +$104K | ﹤0.01% | 3161 |
|
2019
Q3 | $94K | Sell |
636
-195
| -23% | -$28.8K | ﹤0.01% | 3434 |
|
2019
Q2 | $97K | Buy |
831
+374
| +82% | +$43.7K | ﹤0.01% | 3604 |
|
2019
Q1 | $50K | Buy |
+457
| New | +$50K | ﹤0.01% | 3650 |
|
2018
Q4 | – | Sell |
-217
| Closed | -$35K | – | 4413 |
|
2018
Q3 | $35K | Buy |
+217
| New | +$35K | ﹤0.01% | 3835 |
|